Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)Ferdinandos Skoulidis,Adrianus De langen, Luis G. Paz-Ares,Giannis Socrates Mountzios,Alessandra Curioni-Fontecedro,Sebastien Couraud,Annelies Janssens,Danilo Rocco,Kadoaki Ohashi, Mark David Vincent,Jin-Hyoung Kang,Gustavo Schvartsman, Colin R. Lindsay,Kenneth John O'Byrne,Rafal Dziadziuszko, Jon A. Lykkegaard Andersen, Antreas Hindoyan, Tomasz Wilmanski,Yang Wang,Martin H. SchulerJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览8暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
